278 related articles for article (PubMed ID: 18654665)
1. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.
Dickson P; Peinovich M; McEntee M; Lester T; Le S; Krieger A; Manuel H; Jabagat C; Passage M; Kakkis ED
J Clin Invest; 2008 Aug; 118(8):2868-76. PubMed ID: 18654665
[TBL] [Abstract][Full Text] [Related]
2. Immune response hinders therapy for lysosomal storage diseases.
Ponder KP
J Clin Invest; 2008 Aug; 118(8):2686-9. PubMed ID: 18654672
[TBL] [Abstract][Full Text] [Related]
3. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.
Kakkis ED; McEntee MF; Schmidtchen A; Neufeld EF; Ward DA; Gompf RE; Kania S; Bedolla C; Chien SL; Shull RM
Biochem Mol Med; 1996 Aug; 58(2):156-67. PubMed ID: 8812735
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
[TBL] [Abstract][Full Text] [Related]
5. Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I.
Kakkis E; Lester T; Yang R; Tanaka C; Anand V; Lemontt J; Peinovich M; Passage M
Proc Natl Acad Sci U S A; 2004 Jan; 101(3):829-34. PubMed ID: 14715900
[TBL] [Abstract][Full Text] [Related]
6. Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.
Wang RY; Aminian A; McEntee MF; Kan SH; Simonaro CM; Lamanna WC; Lawrence R; Ellinwood NM; Guerra C; Le SQ; Dickson PI; Esko JD
Mol Genet Metab; 2014 Aug; 112(4):286-93. PubMed ID: 24951454
[TBL] [Abstract][Full Text] [Related]
7. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.
Dierenfeld AD; McEntee MF; Vogler CA; Vite CH; Chen AH; Passage M; Le S; Shah S; Jens JK; Snella EM; Kline KL; Parkes JD; Ware WA; Moran LE; Fales-Williams AJ; Wengert JA; Whitley RD; Betts DM; Boal AM; Riedesel EA; Gross W; Ellinwood NM; Dickson PI
Sci Transl Med; 2010 Dec; 2(60):60ra89. PubMed ID: 21123810
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid.
Dickson P; McEntee M; Vogler C; Le S; Levy B; Peinovich M; Hanson S; Passage M; Kakkis E
Mol Genet Metab; 2007 May; 91(1):61-8. PubMed ID: 17321776
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy in feline mucopolysaccharidosis I.
Kakkis ED; Schuchman E; He X; Wan Q; Kania S; Wiemelt S; Hasson CW; O'Malley T; Weil MA; Aguirre GA; Brown DE; Haskins ME
Mol Genet Metab; 2001 Mar; 72(3):199-208. PubMed ID: 11243725
[TBL] [Abstract][Full Text] [Related]
10. Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model.
Hinderer C; Bell P; Louboutin JP; Katz N; Zhu Y; Lin G; Choa R; Bagel J; O'Donnell P; Fitzgerald CA; Langan T; Wang P; Casal ML; Haskins ME; Wilson JM
Mol Genet Metab; 2016 Sep; 119(1-2):124-30. PubMed ID: 27386755
[TBL] [Abstract][Full Text] [Related]
11. Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human alpha-L-iduronidase (laronidase, Aldurazyme).
Kloska A; Bohdanowicz J; Konopa G; Tylki-Szymńska A; Jakóbkiewicz-Banecka J; Czartoryska B; Liberek A; Wegrzyn A; Wegrzyn G
Am J Med Genet A; 2005 Dec; 139(3):199-203. PubMed ID: 16283671
[TBL] [Abstract][Full Text] [Related]
12. Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.
Dickson PI; Ellinwood NM; Brown JR; Witt RG; Le SQ; Passage MB; Vera MU; Crawford BE
Mol Genet Metab; 2012 May; 106(1):68-72. PubMed ID: 22402327
[TBL] [Abstract][Full Text] [Related]
13. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.
Wang D; Belakhov V; Kandasamy J; Baasov T; Li SC; Li YT; Bedwell DM; Keeling KM
Mol Genet Metab; 2012 Jan; 105(1):116-25. PubMed ID: 22056610
[TBL] [Abstract][Full Text] [Related]
14. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation.
Keeling KM; Brooks DA; Hopwood JJ; Li P; Thompson JN; Bedwell DM
Hum Mol Genet; 2001 Feb; 10(3):291-9. PubMed ID: 11159948
[TBL] [Abstract][Full Text] [Related]
15. Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase.
Chen A; Vogler C; McEntee M; Hanson S; Ellinwood NM; Jens J; Snella E; Passage M; Le S; Guerra C; Dickson P
APMIS; 2011 Aug; 119(8):513-21. PubMed ID: 21749451
[TBL] [Abstract][Full Text] [Related]
16. Enzyme-replacement therapy in mucopolysaccharidosis I.
Kakkis ED; Muenzer J; Tiller GE; Waber L; Belmont J; Passage M; Izykowski B; Phillips J; Doroshow R; Walot I; Hoft R; Neufeld EF
N Engl J Med; 2001 Jan; 344(3):182-8. PubMed ID: 11172140
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations.
Vite CH; Wang P; Patel RT; Walton RM; Walkley SU; Sellers RS; Ellinwood NM; Cheng AS; White JT; O'Neill CA; Haskins M
Mol Genet Metab; 2011 Jul; 103(3):268-74. PubMed ID: 21482164
[TBL] [Abstract][Full Text] [Related]
18. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.
Sifuentes M; Doroshow R; Hoft R; Mason G; Walot I; Diament M; Okazaki S; Huff K; Cox GF; Swiedler SJ; Kakkis ED
Mol Genet Metab; 2007 Feb; 90(2):171-80. PubMed ID: 17011223
[TBL] [Abstract][Full Text] [Related]
19. High-dose enzyme replacement therapy in murine Hurler syndrome.
Ou L; Herzog T; Koniar BL; Gunther R; Whitley CB
Mol Genet Metab; 2014 Feb; 111(2):116-22. PubMed ID: 24100243
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R
Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]